Percutaneous Intra-meniscal platelet-rich plasma injection for meniscal tears: A mid-term.

Percutaneous intra-meniscal platelet-rich plasma (PRP) is a promising tool for managing low-grade meniscal injuries in non-athletic patients. The study evaluates the clinical and radiological outcomes of PRP intra-meniscal injection in meniscal tears. Forty-eight patients were injected with 3 injections of PRP at an interval of one week with a standardised technique under sonographic guidance. All the patients had MRI evidence of meniscal injury with failed conservative management for at least 3 months. The IKDC score and VAS score were recorded initially and during follow-ups. MRI was performed on at least 12 months post-injection. Medial meniscus tear (n=33) was most commonly present. The mean follow-up of the patient was 14.4 months (Range: 12-16 months) except for 1 patient. Horizontal or oblique tears were the most common injury suffered by the patients (n=35). According to MRI classification, 6 patients had grade 1 lesions, 28 patients had grade 2 lesions, and 14 patients had grade 3 lesions. The mean IKDC and VAS scores improved significantly at the last follow-up. Pain at the site of the injection for 1-2 days was the most common adverse effect. Two patients were surgically intervened at 4 and 6 months respectively. Intra-meniscal PRP injection can be a promising modality to manage low-grade meniscal injuries. It is easy, and minimally invasive to manage meniscal tears. Although there was no radiological evidence of healing, clinical improvement was seen in all the patients. Further, long-term randomized studies are required to ascertain the benefits.